Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia
The goal of this research study is to find the highest tolerated dose of the combination of selinexor (KPT-330) and sorafenib (Nexavar) that can be given to patients with FLT3-ITD mutated AML or FLT3-mutated high-risk MDS. Another goal of this study is to learn if the highest tolerable dose can help to control the disease.
Disease Group: Leukemia
Treatment Agent: KPT-330,Sorafenib
Treatment Location: Only at MDACC
Primary Objectives Phase I 1. To determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) and dose limiting toxicity (DLT) of the combination of selinexor with sorafenib in FLT3-ITD and -D835 mutated patients with relapsed/refractory acute myeloid leukemia (AML). Phase II 1. To determine the composite CR (CRc) rate including CR (complete remission) + CRp (complete remission with incomplete platelet recovery) + CRi (complete remission with incomplete count recovery) within 3 months of treatment initiation in FLT3-ITD and -D835 mutated patients with relapsed/refractory AML. Secondary Objectives Phase I 1. To determine the composite CRc rate including CR + CRp + CRi within 3 months of treatment initiation in FLT3-ITD and -D835 mutated patients with relapsed/ refractory AML. 2. To determine the partial response (PR), marrow clearance rate, bone marrow blast reduction >/= 50% within 3 months of treatment initiation in FLT3-ITD and -D835 mutated patients with relapsed/ refractory AML. 3. To determine the duration of response (DOR), event-free survival (EFS), overall survival (OS), and number of patients bridged to hematopoetic stem cell transplant (HSCT) and median duration to HSCT from the initiation of the combination of selinexor with sorafenib in FLT3-ITD and -D835 mutated patients with relapsed/ refractory AML. 4. To determine the safety of the combination of selinexor with sorafenib in FLT3-ITD and -D835 mutated patients with relapsed/ refractory AML. Phase II 1. To determine the PR, marrow clearance rate, bone marrow blast reduction >/= 50% within 3 months of treatment initiation in FLT3-ITD and -D835 mutated patients with relapsed/ refractory AML. 2. To determine the DOR, EFS, OS, and number of patients bridged to HSCT and median duration to HSCT from the initiation of the combination of selinexor with sorafenib in FLT3-ITD and -D835 mutated patients with relapsed/ refractory AML. 3. To determine the safety of the combination of selinexor with sorafenib in FLT3-ITD and -D835 mutated patients with relapsed/ refractory AML. Exploratory Objectives 1. To evaluate the response rate, EFS and OS in FLT3 mutated/NPM1 wild-type patients versus FLT3 mutated/NPM1 mutated versus FLT3 wild-type/NPM1 mutated patients treated with the combination of selinexor and sorafenib. 2. Quantitative changes of FLT3-ITD and -D835 allelic burden with time in patients treated with the combination of selinexor and sorafenib. 3. To evaluate the extent of pharmacodynamics biomarker (such as p-FLT3, p-p70S6K, pERK) inhibition and the induction of apoptosis in the bone marrow and peripheral blasts following treatment with the combination of selinexor and sorafenib. 4. To investigate possible relationships between selinexor and other baseline gene expression signatures and clinical response. 5. To store and/or analyze surplus blood or tissue including bone marrow, if available, for potential future exploratory research into factors that may influence development of AML and/or response to selinexor (where response is defined broadly to include efficacy, tolerability or safety). 6. To evaluate the pharmacodynamic effects of treatment on induction/inhibition of XPO1 using qRT-PCR and on plasma protein/cytokine levels.
IRB Review and Approval Date: 12/08/2015
Recruitment Status: Open
Projected Accrual: N/A
1) FLT3-ITD and/or FLT3-D835 mutated patients 18 years of age or older
with relapsed/ refractory AML (any number of relapses) including
patients who may have been previously exposed to one or more
FLT3-inhibitor therapies will be eligible for the phase I portion of
2) Phase II FLT3-ITD and/or FLT3-D835 mutated relapsed/refractory patients: Patients should have a diagnosis of AML (de novo or transformed from hematologic malignancies). Patients with high-risk myelodysplastic syndrome (MDS) (defined as having >/= 10% blasts in the bone marrow) or patients with Chronic Myelomonocytic Leukemia (CMML) (having >/= 10% blasts in the bone marrow) may also be eligible after discussion with Principal Investigator (PI). The patients should have one of the following features: 1. Patients with AML should have failed any prior induction therapy or have relapsed after prior therapy. 2. Patients with high-risk MDS or high-risk CMML should have failed any prior therapy for the MDS or CMML. 3. Patients with MDS or CMML who received therapy for the MDS or CMML and progress to AML are eligible at the time of diagnosis of AML regardless any prior therapy for AML. The WHO classification will be used for AML.
3) Patients must be eligible for one of two cohorts: Cohort 1 (FLT3 and/or FLT3-D835 inhibitor failure cohort) in FLT3-ITD and/or FLT3-D835 mutated relapsed/refractory AML who have failed therapy with up to two prior salvage regimens (SCT or stem cell therapy for patients who previously underwent SCT/stem cell therapy in remission will not be considered a salvage regimen) and have previously been exposed at least one prior FLT3 inhibitor. Cohort 2 (FLT3 inhibitor naive cohort) in FLT3-ITD and/or FLT3-D835 mutated relapsed/refractory who have failed therapy with up to two prior salvage regimens (SCT or stem cell therapy for patients who previously underwent SCT/stem cell therapy in remission will not be considered a salvage regimen) with no prior exposure to any FLT3 inhibitor.
4) Age >/=18 years
5) ECOG Performance Status </=2
6) Patients should have estimated life expectancy of >3 months at study entry
7) Adequate hepatic (serum total bilirubin </= 2.0 x upper limit normal (ULN) (or </= 3.0 x ULN if deemed to be elevated due to leukemia), alanine aminotransferase and/or aspartate transaminase </= 3.0 x ULN (or </= 5.0 x ULN if deemed to be elevated due to leukemia), and renal function (creatinine </= 2.0 mg/dL).
8) Patients must provide written informed consent.
9) In the absence of rapidly progressing disease, the interval from prior treatment to time of initiation of selinexor and sorafenib administration will be at least 2 weeks for cytotoxic agents or at least 5 half-lives for cytotoxic/noncytotoxic agents. The use of chemotherapeutic or anti-leukemic agents is not permitted during the study with the following exceptions: (1) intrathecal (IT) therapy for patients with controlled CNS leukemia at the discretion of the PI and with the agreement of the Sponsor. Controlled CNS leukemia is defined by the absence of active clinical signs of CNS disease and no evidence of CNS leukemia on the most recent 2 simultaneous CSF evaluations. (2) Use of one dose of cytarabine (up to 2 g/m2) or hydroxyurea for patients with rapidly proliferative disease is allowed before the start of study therapy and for the first four weeks on therapy. These medications will be recorded in the case-report form.
10) Baseline ejection fraction must be >/= 40%.
11) Females must be surgically or biologically sterile or postmenopausal (amenorrheic for at least 12 months) or if of childbearing potential, must have a negative serum or urine pregnancy test within 72 hours before the start of the treatment.
12) Women of childbearing potential must agree to use an adequate method of contraception during the study and until 3 months after the last treatment. Males must be surgically or biologically sterile or agree to use an adequate method of contraception during the study until 3 months after the last treatment. Adequate methods of contraception include: Total abstinence when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment
13) (Continued from Criteria 12) Male sterilization (at least 6 months prior to screening). For female patients on the study, the vasectomized male partner should be the sole partner for that patient Combination of any of the two following (a+b or a+c or b+c) Use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception Placement of an intrauterine device (IUD) or intrauterine system (IUS) Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/ vaginal suppository
14) (Continued from Criteria 13) In case of use of oral contraception, women should have been stable on the same pill before taking study treatment. Note: Oral contraceptives are allowed but should be used in conjunction with a barrier method of contraception due to unknown effect of drug-drug interaction. Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.
1) Patients with known allergy or hypersensitivity to selinexor,
sorafenib or any of its components.
2) Subject has concurrent, uncontrolled medical condition, laboratory abnormality, or psychiatric illness, which could place him/her at unacceptable risk.
3) Patients who have had any major surgical procedure within 14 days of Day 1.
4) Patients currently receiving any other standard or investigational therapy for the treatment of AML.
5) Patients unwilling or unable to comply with the protocol.
6) Patients receiving concomitant treatment with strong CYP3A4 inhibitors, unless such drugs are considered critical for the well being of the patient and not adequate alternatives are available. Strong CYP3A4 inhibitors include the following medications: itraconazole, ketoconazole, miconazole, voriconazole; amprenavir, atazanavir, fosamprenavir, indinavir, nelfinavir, ritonavir; ciprofloxacin, clarithromycin, diclofenac, doxycycline, enoxacin, isoniazid, ketamine, nefazodone, nicardipine, propofol, quinidine, telithromycin.
7) Patients with any severe gastrointestinal or metabolic condition that could interfere with absorption of oral medications.
8) Patients who are in blast transformation of chronic myeloid leukemia (CML). Prior MDS or CMML is acceptable.
9) Patient has a concurrent active malignancy under treatment.
10) Unstable cardiovascular function: • Symptomatic ischemia, or • Uncontrolled clinically significant conduction abnormalities (i.e., ventricular tachycardia on antiarrhythmic agents are excluded; 1st degree atrioventricular (AV) block or asymptomatic left anterior fascicular block/right bundle branch block (LAFB/RBBB) will not be excluded), or • Congestive heart failure (CHF) NYHA Class = 3, or • Myocardial infarction (MI) within 3 months. • Left ventricular ejection fraction < 40 %. • Hypertension > 140 mm Hg systolic or > 90 mm Hg diastolic with or without antihypertensive therapy.
11) Uncontrolled infection at the time of enrollment. Infections controlled on concurrent anti-microbial agents are acceptable, and anti-microbial prophylaxis per institutional guidelines is acceptable.
12) Known active hepatitis B virus (HBV) or C virus (HCV) infection; or known to be positive for HCV ribonucleic acid (RNA) or HBsAg (HBV surface antigen).
13) Known human immunodeficiency virus (HIV) infection.
14) Female subjects who are pregnant or breastfeeding.
15) Acute promyelocytic leukemia.
16) Any medical condition, which in the investigator's opinion, could compromise the patient's safety.
Information and next steps
Phase I/Phase II
For general questions about clinical trials: